Exelixis, Inc. (LON:0IJO)

Market Cap	7.57B
Revenue (ttm)	1.63B
Net Income (ttm)	439.62M
Shares Out	n/a
EPS (ttm)	1.52
PE Ratio	17.23
Forward PE	11.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,921
Average Volume	4,807
Open	36.42
Previous Close	36.68
Day's Range	35.90 - 37.86
52-Week Range	23.06 - 51.98
Beta	n/a
RSI	28.37
Earnings Date	Aug 5, 2025

About Heartland Financial USA

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1994
• Employees: 1,147
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IJO

Financial Performance

In 2024, Exelixis's revenue was $2.17 billion, an increase of 18.49% compared to the previous year's $1.83 billion. Earnings were $521.27 million, an increase of 150.89%.